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a b s t r a c t 
This post-hoc analysis compared the pharmacokinetics and clinical outcomes of ceftaroline fosamil 600 
mg every 12 (q12h) versus every 8 hours (q8h) in patients with acute bacterial skin and skin-structure 
infection (ABSSSI) and signs of sepsis. Clinical outcomes at test-of-cure in patients with ABSSSI and sys- 
temic inﬂammatory signs/systemic inﬂammatory response syndrome (SIRS) as well as ceftaroline mini- 
mum inhibitory concentrations (MICs) against baseline pathogens were compared between the COVERS 
trial (ceftaroline fosamil 600 mg q8h, 2-h infusion) and the CANVAS 1 and 2 trials (ceftaroline fosamil 
600 mg q12h, 1-h infusion). Ceftaroline exposure among patients in COVERS with or without markers 
of sepsis was compared using population pharmacokinetic modelling. In COVERS, 62% (312/506) and 41% 
(208/506) of ceftaroline fosamil-treated patients had ≥1 systemic inﬂammatory sign or SIRS, respectively, 
compared with 55% (378/693) and 22% (155/693), respectively, in the CANVAS trials. Clinical cure rates 
for the modiﬁed intent-to-treat population in COVERS and CANVAS were similar for ceftaroline fosamil- 
treated patients with ≥1 sign of sepsis [82% (255/312) and 85% (335/394)] and for those with SIRS [84% 
(168/199) and 85% (131/155)]. Ceftaroline MIC distributions were similar across trials. Sepsis did not af- 
fect predicted individual steady-state ceftaroline exposure. Clinical cure rates in patients with ≥1 systemic 
inﬂammatory sign or SIRS were comparable for both ceftaroline fosamil dosage regimens. Pathogen sus- 
ceptibilities to ceftaroline were similar across trials. Ceftaroline exposure was not affected by disease 
severity. Ceftaroline fosamil 600 mg q12h is a robust dosage regimen for most ABSSSI patients with sep- 
sis [ClinicalTrials.gov ID: NCT01499277, NCT00424190, NCT00423657]. 
© 2019 The Authors. Published by Elsevier B.V. 
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0924-8579/© 2019 The Authors. Published by Elsevier B.V. This is an open access article u. Introduction 
Acute bacterial skin and skin-structure infections (ABSSSIs)
nd complicated skin and soft-tissue infections (cSSTIs) include
ellulitis/erysipelas, wound infection and major cutaneous abscess
1,2] , imposing a substantial burden on healthcare systems. Be-
ween 2005 and 2010, the incidence of SSTI in the USA was ca. 48
er 10 0 0 person-years [3] ; currently, up to 30 0 0 0 0 surgical site
nfections occur each year, including those of the skin and subcu-
aneous tissue [4] . SSTIs can be serious, requiring hospitalisation
nd surgical procedures, and occasionally can cause bacteraemia
nd death [5] . Factors associated with ABSSSI onset and clinicalnder the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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d  ailure of ABSSSI treatment include obesity and low antibiotic
osage at discharge [6,7] . 
Ceftaroline, the active metabolite of the prodrug ceftaroline fos-
mil, is a cephalosporin antibiotic with in vitro activity against
any of the common bacteria associated with ABSSSI, includ-
ng Staphylococcus aureus [both methicillin-susceptible S. aureus
MSSA) and methicillin-resistant S. aureus (MRSA)], Streptococcus
yogenes, Streptococcus agalactiae , and non-extended-spectrum β-
actamase (ESBL)-producing Escherichia coli, Klebsiella pneumoniae 
nd Klebsiella oxytoca [8,9] . In the pivotal phase III CANVAS 1 and
 trials, ceftaroline fosamil 600 mg given as a 1-h intravenous (i.v.)
nfusion every 12 h (q12h) was shown to be non-inferior to van-
omycin plus aztreonam for the treatment of ABSSSI [10–12] . These
esults supported the US Food and Drug Administration (FDA) and
uropean Medicines Agency (EMA) approvals of ceftaroline fosamil
00 mg q12h (adjusted for renal function) for the treatment of
dults with ABSSSI and cSSTI, respectively [8,9] . 
The presence of sepsis can impact the pharmacokinetics of
ome antibiotics and thus potentially affect antibiotic eﬃcacy in
atients with ABSSSI. Septic patients in the intensive care unit
ave shown an increased volume of distribution ( V d ) and increased
learance. An increase in V d in these patients has been shown to
e due to capillary leakage and endothelial damage, which can re-
ult in subtherapeutic dosing following administration of antibi-
tics. Clearance is variable and is dependent on the individual’s
isease state. Variable exposure to drug as a result of changes in
 d and clearance can, in turn, result in variable responsiveness to
reatment both in terms of eﬃcacy and toxicity, and this can im-
act mortality rates in these patients [13–15] . 
The phase III COVERS trial was conducted to assess a ceftaro-
ine fosamil dosage regimen of 600 mg as a 2-h infusion every
 h (q8h) in patients with ABSSSI with systemic inﬂammatory re-
ponse syndrome (SIRS) or underlying co-morbidities and, on aver-
ge, a greater lesion size [12] . Results from COVERS showed that
eftaroline fosamil 600 mg q8h was non-inferior to vancomycin
lus aztreonam in these patients [12] . 
The objective of this post-hoc analysis was to compare ceftaro-
ine fosamil 600 mg q12h versus 600 mg q8h for the treatment of
BSSSI in patients with signs of sepsis, ﬁrst by comparing clinical
utcomes and pathogen susceptibilities in the COVERS trial with
he previously published CANVAS trials, and second by using pop-
lation pharmacokinetic (PK) modelling to compare ceftaroline ex-
osure in patients with or without markers of sepsis. 
. Materials and methods 
.1. Study design 
COVERS (NCT01499277) and CANVAS 1 and 2 (NCT00424190
nd NCT00423657) were phase III, multicentre, randomised,
ouble-blind, comparative safety and eﬃcacy trials of i.v. ceftaro-
ine fosamil versus vancomycin plus aztreonam for the treatment
f ABSSSI [10–12] . Patients were randomised to receive ceftaroline
osamil or vancomycin plus aztreonam at a ratio of 2:1 in COV-
RS and 1:1 in CANVAS 1 and 2. In COVERS, ceftaroline fosamil
as administered at 600 mg q8h and vancomycin was adminis-
ered at 15 mg/kg q12h with aztreonam at 1 g q8h. In CANVAS 1
nd 2, ceftaroline fosamil was administered at 600 mg q12h and
ancomycin plus aztreonam were each administered at 1 g q12h.
eftaroline fosamil dosages were adjusted for patients with base-
ine creatinine clearance (CL Cr ) ≤50 mL/min, and vancomycin plus
ztreonam dosages were adjusted according to the respective prod-
ct labelling and institutional practice guidelines. Treatments were
iven for 5–14 days in all trials. The primary outcome measure
or all three trials was the clinical cure rate at test-of-cure (TOC)n the modiﬁed intent-to-treat (MITT) and clinically evaluable (CE)
atient populations. 
.2. Patients and disease characteristics 
The COVERS and CANVAS trials enrolled adult patients with
SSTI. The entire COVERS patient population, and a proportion of
hose in the CANVAS trials, met the FDA deﬁnition of ABSSSI [1] .
nclusion and exclusion criteria for the CANVAS trials have been
escribed previously [10,11] . In brief, patients had a diagnosis of
SSTI (deﬁned as deep extensive cellulitis, major cutaneous abscess
equiring surgical drainage, or infected wound, ulcer or burn) of
uﬃcient severity to warrant hospitalisation and ≥5 days of par-
nteral antibacterial therapy. Inclusion and exclusion criteria for
OVERS were similar to the CANVAS trials, with an additional re-
uirement of ABSSSI with surrounding area of erythema, oedema
nd/or induration with surface area ≥75 cm 2 , reﬂecting regula-
ory guidance at the time the study was initiated [1,12] ; of note,
OVERS (but not CANVAS) excluded patients with diabetic foot in-
ections. Disease characteristics assessed at baseline included sys-
emic signs of infection, presence of SIRS [deﬁned as the presence
f at least two of the following symptoms at baseline: temperature
 36 °C or > 38 °C; heart rate > 90 beats/min; respiratory rate > 20
reaths/min or on blood gas, a PaCO 2 < 32 mmHg (4.3 kPa); white
lood cell (WBC) count < 40 0 0 cells/mm 3 or > 12 0 0 0 cells/mm 3 ,
r > 10% band forms (immature WBCs)] and an elevated C-reactive
rotein (CRP) level. Patients were required to give informed con-
ent prior to enrolment in the trials. 
.3. Microbiology 
Baseline pathogen susceptibilities to ceftaroline [minimum in-
ibitory concentrations (MICs)] were determined using Clinical and
aboratory Standards Institute (CLSI) methodology [16] by a central
eference laboratory. 
.4. Clinical outcomes 
Clinical cure was deﬁned as total resolution of all signs and
ymptoms of the baseline infection or improvement such that no
urther antimicrobial therapy was necessary. Outcome was deter-
ined at the TOC time point (8–15 days after the last dose of
tudy drug) in the MITT population (all randomised patients who
eceived any study medication) and CE population, a subset of
he MITT population who had a diagnosis of ABSSSI, had no non-
ligible infections, received a prespeciﬁed minimum of study drug,
ad an evaluation at the TOC (or were determined to be a clini-
al failure at end of therapy) and did not receive any systemically
ctive antibacterial agents that may have affected the infection
nder study [12,17] . Clinical cure rates were summarised for the
ITT and CE populations overall and for patient subgroups with
t least one systemic sign of inﬂammation, or sepsis [fever > 38 °C,
ypothermia < 36 °C, elevated WBC count ( > 10 0 0 0 cells/mm 3 or
ands > 10%)], at least two severe signs or symptoms (erythema,
welling, tenderness or warmth that was designated as ‘severe’ by
he investigator) or SIRS. As body weight and renal function have
lso been shown to impact ceftaroline pharmacokinetics [18,19] ,
linical cure rates were summarised by body mass index (BMI) and
L Cr to compare outcomes across BMI and CL Cr subgroups. Finally,
linical cure rates were also summarised by baseline pathogen.
afety was assessed in all randomised patients who received at
east one dose of study therapy. 
.5. Population pharmacokinetic modelling 
The ceftaroline population PK model used in this analysis was
eveloped using a large patient PK data set that included data
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Table 1 
Patient demographics and baseline characteristics of the modiﬁed intent-to-treat (MITT) population a 
Characteristic COVERS CANVAS 1 and 2 
Ceftaroline fosamil 
( n = 506) 
Vancomycin + aztreonam 
( n = 255) 
Ceftaroline fosamil 
( n = 693) 
Vancomycin + aztreonam 
( n = 685) 
Age (years) (mean ± S.D.) 52.6 ± 16.5 53.6 ± 16.3 47.5 ± 17.0 48.4 ± 16.6 
Sex 
Female 196 (38.7) 107 (42.0) 249 (35.9) 266 (38.8) 
Male 310 (61.3) 148 (58.0) 4 4 4 (64.1) 419 (61.2) 
Race 
White 341 (67.4) 160 (62.7) 506 (73.0) 512 (74.7) 
Black or African–American 13 (2.6) 13 (5.1) 48 (6.9) 41 (6.0) 
Asian 126 (24.9) 64 (25.1) 6 (0.9) 5 (0.7) 
American Indian or Alaska Native 1 (0.2) 0 6 (0.9) 4 (0.6) 
Native Hawaiian or other Paciﬁc 
Islander 
– – 2 (0.3) 2 (0.3) 
Multiracial/other/unknown 25 (4.9) 18 (7.1) 125 (18.0) 121 (17.7) 
BMI (kg/m 2 ) [median (range)] 26.6 (15.0–50.0) 26.6 (14.0–50.0) 26.9 (14.1–74.1) 27.4 (16.6–66.5) 
Baseline CL Cr (mL/min) 
b 
> 30 to ≤50 31 (6.1) 17 (6.7) 23 (3.3) 26 (3.8) 
> 50 to ≤80 91 (18.0) 46 (18.0) 99 (14.3) 98 (14.3) 
> 80 362 (71.5) 183 (71.8) 569 (82.1) 559 (81.6) 
Baseline CRP (mg/L) c 
≤50 178 (35.2) 100 (39.2) 396 (57.1) 387 (56.5) 
> 50 to ≤150 178 (35.2) 80 (31.4) 177 (25.5) 166 (24.2) 
> 150 139 (27.5) 68 (26.7) 98 (14.1) 111 (16.2) 
Primary diagnosis of cellulitis 300 (59.3) 136 (53.3) 249 (35.9) 273 (39.9) 
Co-morbid conditions 
Diabetes mellitus 84 (16.6) 38 (14.9) 122 (17.6) 120 (17.5) 
Peripheral vascular disease 27 (5.3) 11 (4.3) 93 (13.4) 93 (13.6) 
Infection area (cm 2 ) [median 
(range)] 
400 (75–5040) 400 (77–6048) 156 (1–3150) 150 (0.04–4950) 
Prior antibiotic therapy 240 (47.4) 116 (45.5) 276 (39.8) 260 (38.0) 
≥1 systemic inﬂammatory sign d 312 (61.7) 166 (65.1) 378 (54.5) 363 (53.0) 
≥2 severe signs and/or symptoms e 329 (65.0) 165 (64.7) 372 (53.7) 379 (55.3) 
SIRS f 199 (39.3) 105 (41.2) 155 (22.4) 163 (23.8) 
S.D., standard deviation; BMI, body mass index; CL Cr , creatinine clearance; CRP, C-reactive protein; WBC, white blood cell; SIRS, systemic inﬂammatory response syndrome. 
a Data are n (%) unless otherwise stated. 
b 9 patients had CL Cr > 20 to < 30 mL/min and 22 patients had missing CL Cr data in COVERS; 4 patients had CL Cr ≤30 mL/min in CANVAS 1 and 2. 
c 18 patients had missing CRP data in COVERS; 43 patients had missing CRP data in CANVAS 1 and 2. 
d Systemic inﬂammatory signs were fever > 38 °C, hypothermia < 36 °C, elevated WBC count ( > 10 0 0 0 cells/mm 3 ) or bands > 10%. 
e Severe local signs were erythema, swelling, tenderness or warmth that was designated as ‘severe’ by the investigator. 
f SIRS criteria were deﬁned as the presence of at least two of the following symptoms at baseline: temperature < 36 °C or > 38 °C; heart rate > 90 beats/min; respiratory 
rate > 20 breaths/min, or on blood gas, a PaCO 2 , < 32 mmHg (4.3 kPa); WBC count < 40 0 0 cells/mm 
3 or > 12 0 0 0 cells/mm 3 , or > 10% band forms (immature WBCs). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d  
t  
a
3
3
 
m  
a  
a  
i  
C  
v  
f  
t  
(
 
w  
a  
C  
V  
l  
s  
(  
1  from 14 phase I trials in healthy subjects (with normal renal
function or renal impairment), 1 phase II trial in patients with
cSSTI, 3 phase III trials in patients with cSSTI (CANVAS 1, CANVAS
2 and COVERS) and 3 phase III trials in patients with community-
acquired pneumonia [10–12,19–28] . Patient PK data were obtained
in COVERS and in a subset of 45 patients in CANVAS 1 and 2 trials
by sparse PK sampling over a single dosing interval (i.e. 8 h) on
Day 3, with intensive PK samples taken in a subset of patients
[29] . The population PK model was derived from ﬁrst-order con-
ditional estimation with the interaction model using the software
program NONMEM v.7.2.0 (ICON plc, Dublin, Ireland). Details
related to the PK modelling have been previously described [30] .
Ceftaroline PK proﬁles were estimated for individual patients in
COVERS with available ceftaroline PK data. Steady-state ceftaroline
exposures [maximum plasma concentration ( C max,ss ) and area un-
der the concentration–time curve (AUC ss )] were derived from the
individual predicted ceftaroline concentration–time courses from
the population PK model using non-compartmental analysis. To
assess whether the presence of markers of systemic inﬂammation
or sepsis had any impact on ceftaroline exposures, AUCss and
Cmax,ss were compared for the following patient subgroups: fever
≤38 °C or > 38 °C; WBC count ≤12 0 0 0/mm 3 or > 12 0 0 0/mm 3 ; CRP
≤50 mg/L, > 50 mg/L to ≤150 mg/L or > 150 mg/L; and presence
or absence of SIRS or bacteraemia at baseline [29] . 
2.6. Statistical analyses 
Patient outcomes are presented using descriptive statistics, and
between-group outcome differences (95% conﬁdence interval) wereetermined using the Miettinen & Nurminen method [31] . Full de-
ails of the statistical analyses used in the COVERS and CANVAS 1
nd 2 trials have previously been described [10,11] . 
. Results 
.1. Patient demographics and baseline characteristics 
Patient demographics and baseline characteristics are sum-
arised in Table 1 . Most patients were male and white. Over-
ll, baseline characteristics, including BMI, co-morbidities and prior
ntibiotic therapy, were similar between the patient populations
n COVERS and the CANVAS trials. Patients were slightly older in
OVERS compared with the CANVAS trials (mean ± standard de-
iation age, 52.6 ± 16.5 years vs. 47.5 ± 17.0 years for ceftaroline
osamil-treated patients) and there was a greater proportion of pa-
ients with a primary cSSTI diagnosis of cellulitis in COVERS [300
59.3%) vs. 249 (35.9%) for ceftaroline fosamil-treated patients]. 
As expected based on inclusion criteria, more severe ABSSSI
as observed in patients in COVERS; the median (range) infection
rea was greater among ceftaroline fosamil-treated patients from
OVERS [400 (75–5040) cm 2 ] compared with those from CAN-
AS 1 and 2 [156 (1–3150) cm 2 ]. A greater proportion of ceftaro-
ine fosamil-treated patients from COVERS also had at least one
ystemic inﬂammatory sign [312/506 (61.7%) COVERS vs. 378/693
54.5%) CANVAS 1 and 2] and SIRS [208/506 (41.1%) COVERS vs.
55/693 (22.4%) CANVAS 1 and 2] at baseline. Compared with
G.R. Corey, M.H. Wilcox and J. Gonzalez et al. / International Journal of Antimicrobial Agents 53 (2019) 830–837 833 
Table 2 
Susceptibility to ceftaroline of pathogens isolated at baseline in the modiﬁed intent-to-treat (MITT) population 
Pathogen COVERS CANVAS 1 and 2 
Isolates ( n ) a MIC range b MIC 90 
b , c Isolates ( n ) a MIC range b MIC 90 
b 
Gram-positive bacteria 
Staphylococcus aureus d , e 217 0.06–1.0 0.5 399 0.06–2.0 0.5 
MSSA 164 0.06–0.5 0.25 235 0.06–0.5 0.25 
MRSA 54 0.25–1.0 0.5 164 0.25–2.0 0.5 
Streptococci 
Streptococcus pyogenes f 25 ≤0.008 ≤0.008 61 ≤0.0 04–0.0 08 ≤0.004 
Streptococcus agalactiae f 16 ≤0.008–0.015 0.015 22 0.008–0.015 0.015 
Streptococcus dysgalactiae 12 ≤0.008–0.06 0.015 13 ≤0.0 04–0.0 08 0.008 
Streptococcus anginosus group 21 ≤0.008–0.03 0.03 14 ≤0.004–0.06 0.03 
Enterococcus faecalis 13 0.5–64 8 27 0.25–16 8 
Gram-negative bacteria g 
Escherichia coli (non-ESBL-producing) 26 ≤0.015–8 1.0 23 0.015 to > 16 1.0 
Klebsiella oxytoca 8 0.03–0.25 – 11 0.03–0.25 0.25 
Klebsiella pneumoniae 12 0.06 to > 32 > 32 18 0.03 to > 16 > 16 
Morganella morganii 7 0.03–0.12 – 11 0.06 to > 16 > 16 
Proteus mirabilis 11 0.03 to > 32 0.12 16 ≤0.008 to > 16 > 16 
MIC, minimum inhibitory concentration; MIC 90 , MIC required to inhibit 90% of the isolates; FDA, US Food and Drug Administration; CLSI, Clinical and Laboratory Standards 
Institute; MSSA, methicillin-susceptible S. aureus ; MRSA, methicillin-resistant S. aureus ; ESBL, extended-spectrum β-lactamase. 
a Some pathogens that were isolated were not able to be tested. 
b MIC range and MIC 90 expressed in mg/L. 
c MIC 90 not calculated when n < 10. 
d Patients with both MRSA and MSSA were counted only once. 
e FDA/CLSI ceftaroline susceptible/resistant breakpoints ≤1/ ≥4 mg/L. 
f FDA/CLSI ceftaroline susceptible breakpoint ≤0.5 mg/L. 
g FDA/CLSI ceftaroline susceptible/resistant breakpoint for Enterobacteriaceae ≤0.5/ ≥2 mg/L [32] . 
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cANVAS 1 and 2, a greater proportion of patients in COVERS had
levated baseline CRP levels. 
.2. Baseline pathogens 
The most common pathogens isolated and tested at baseline in
he COVERS patient population were MSSA ( n = 164; 39%), MRSA
 n = 54; 13%), non-ESBL-producing E. coli ( n = 26; 6%) and S. pyo-
enes ( n = 25; 6%). In the CANVAS trials, MSSA ( n = 235; 36%),
RSA ( n = 164; 25%), S. pyogenes ( n = 61; 9%) and Enterococcus fae-
alis ( n = 27; 4%) were the most commonly isolated pathogens. The
roportion of patients with no baseline pathogen identiﬁed was
igher in COVERS ( n = 378; 49.0%) compared with the CANVAS tri-
ls ( n = 324; 23.2%), reﬂecting the higher proportion of patients
ith cellulitis in the COVERS trial. 
The ceftaroline susceptibility of pathogens isolated at baseline
ere generally similar between the COVERS and CANVAS trials
 Table 2 ). Both in COVERS and the CANVAS trials, the ceftaroline
IC (range) and MIC 90 (MIC required to inhibit 90% of the iso-
ates) for MSSA isolates were 0.06–0.5 mg/L and 0.25 mg/L, re-
pectively. Ceftaroline susceptibility among MRSA isolates was as
ollows: COVERS MIC range, 0.25–1.0 mg/L, MIC 90 , 0.5 mg/L; and
ANVAS MIC range, 0.25–2.0 mg/L, MIC 90 , 0.5 mg/L. The ceftaro-
ine MIC range and MIC 90 of S. pyogenes isolates from COVERS were
oth ≤0.008 mg/L; the ceftaroline MIC range and MIC 90 of S. pyo-
enes isolates from the CANVAS trials were < 0.0 04–0.0 0 08 mg/L
nd ≤0.004 mg/L, respectively. 
.3. Clinical outcomes (modiﬁed intent-to-treat population) 
Overall clinical cure rates at TOC for ceftaroline fosamil were
8.3% (396/506) in the COVERS trial and 85.9% (595/693) in the
ANVAS trials. For patients treated with vancomycin plus aztre-
nam, overall clinical cure rates were 79.2% (202/255) in the COV-
RS trial and 85.5% (586/685) in the CANVAS trials. Clinical cure
ates by inﬂammatory sign, BMI and CL Cr subgroups and overall are
ummarised in Table 3 . Clinical cure rates for ceftaroline fosamil-
reated patients across all subgroups with systemic inﬂammatoryigns or SIRS were broadly similar in the COVERS and CANVAS
rials, ranging from 79% to 85% in COVERS and from 83% to 89%
n the CANVAS trials. For comparison, the clinical cure rates for
ancomycin plus aztreonam ranged from 72% to 88% in the COV-
RS trial and from 84% to 90% in the CANVAS trials. Among cef-
aroline fosamil-treated patients with at least one systemic sign
f inﬂammation, or sepsis, clinical cure was observed in 81.7% of
atients (255/312) in COVERS and 85.0% (335/394) in CANVAS 1
nd 2. Among ceftaroline fosamil-treated patients with SIRS, clini-
al cure was observed in 84.4% (168/199) from COVERS and 84.5%
131/155) from CANVAS 1 and 2. Clinical cure rates by inﬂamma-
ory sign and overall for the CE population were similar to those
n the MITT population (Supplementary Table S1). 
Clinical cure rates were generally comparable between ceftaro-
ine fosamil-treated BMI subgroups in the COVERS and CANVAS tri-
ls, with the exception of a small number of patients with BMI
 18.5 kg/m 2 [clinical cure rate 8/15 (53.3%) in COVERS compared
ith 11/15 (73.3%) in CANVAS]. Clinical cure rates for ceftaroline
osamil-treated patient subgroups with BMI ≥18.5 to < 25, ≥25
o < 30 and ≥30 kg/m 2 ranged from 75.2% to 84.5% in COVERS
nd from 84.5% to 91.2% in the CANVAS trials. A small proportion
f ceftaroline fosamil-treated patients had moderate renal impair-
ent (CL Cr > 30 to ≤50 mL/min) at baseline in the COVERS and
ANVAS trials [31 (6.1%) and 23 (3.3%), respectively]. Clinical cure
ates for ceftaroline fosamil-treated patients with moderate renal
mpairment were 23/31 (74.2%) in COVERS and 19/23 (82.6%) in
he CANVAS trials. Clinical cure rates for BMI and CL Cr subgroups
n the CE population were similar to those in the MITT population
Supplementary Table S1). 
Clinical cure rates by baseline pathogen (medically evaluable
opulation) are summarised in Table 4 . Among ceftaroline fosamil-
reated patients with infections caused by MSSA, clinical cure rates
ere 93.6% (88/94) and 93.0% (212/228) in COVERS and CANVAS 1
nd 2, respectively. Clinical cure was observed 84.0% (21/25) and
3.4% (142/152) of ceftaroline fosamil-treated patients with infec-
ions caused by MRSA from COVERS and CANVAS 1 and 2, respec-
ively; all MRSA isolates from COVERS and CANVAS 1 and 2 had a
eftaroline MIC of ≤1 mg/L and ≤2 mg/L, respectively. 
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Table 3 
Clinical cure rates at test-of-cure overall and among subgroups of patients with systemic signs of infection, systemic inﬂammatory response syndrome (SIRS), and body mass 
index (BMI) and baseline creatinine clearance (CL Cr ) categories in the modiﬁed intent-to-treat (MITT) population 
Patient population COVERS CANVAS 1 and 2 
Ceftaroline fosamil 
[ n / N (%)] 
Vancomycin + aztreonam 
[ n / N (%)] 
Between-group 
difference (95% CI) 
Ceftaroline fosamil [ n / N 
(%)] 
Vancomycin + aztreonam 
[ n / N (%)] 
Between-group 
difference (95% CI) 
Overall 396/506 (78.3) 202/255 (79.2) –1.0 (–6.9 to 5.4) 595/693 (85.9) 586/685 (85.5) 0.3 ( −3.4 to 4.0) 
≥1 systemic 
inﬂammatory sign a 
255/312 (81.7) 137/166 (82.5) –0.8 ( −7.7 to 6.8) 335/378 (88.6) 326/363 (89.8) −1.0 ( −6.0 to 4.0) 
≥2 severe signs and/or 
symptoms b 
259/329 (78.7) 137/165 (83.0) –4.3 (–11.3 to 3.3) 330/372 (88.7) 332/379 (87.6) 1.1 ( −3.6 to 5.8) 
Fever 179/211 (84.8) 104/118 (88.1) –3.3 ( −10.6 to 4.9) 185/211 (87.7) 181/201 (90.0) −2.4 ( −8.6 to 3.8) 
Elevated WBC count c 177/224 (79.0) 75/104 (72.1) 6.9 ( −2.8 to 17.5) 205/246 (83.3) 213/254 (83.9) −0.5 ( −7.1 to 6.0) 
SIRS d 168/199 (84.4) 83/105 (79.0) 5.4 ( −3.5 to 15.2) 131/155 (84.5) 140/163 (85.9) −1.4 ( −9.4 to 6.5) 
Baseline CRP (mg/L) 
≤50 149/178 (83.7) 83/100 (83.0) 0.7 (–8.0 to 10.5) 346/396 (87.4) 333/387 (86.0) 1.3 ( −3.5 to 6.1) 
> 50 to ≤150 136/178 (76.4) 67/80 (83.8) –7.4 (–16.9 to 3.8) 156/177 (88.1) 138/166 (83.1) 5.0 ( −2.5 to 12.7) 
> 150 105/139 (75.5) 49/68 (72.1) 3.5 (–8.8 to 16.9) 76/98 (77.6) 95/111 (85.6) −8.0 ( −18.9 to 2.5) 
BMI (kg/m 2 ) e , f 
< 18.5 8/15 (53.3) 6/9 (66.7) −13.3 ( −48.2 to 27.4) 11/15 (73.3) 5/7 (71.4) 1.9 
≥18.5 to < 25 145/185 (78.4) 67/87 (77.0) 1.4 ( −8.7 to 12.7) 201/238 (84.5) 182/223 (81.6) 2.8 ( −4.0 to 9.8) 
≥25 to < 30 115/153 (75.2) 71/86 (82.6) −7.4 ( −17.5 to 3.8) 197/216 (91.2) 210/227 (92.5) −1.3 ( −6.7 to 3.9) 
≥30 125/148 (84.5) 58/73 (79.5) 5.0 ( −5.3 to 16.9) 186/222 (83.8) 188/227 (82.8) 1.0 ( −6.0 to 7.9) 
CL Cr (mL/min) 
g 
> 30 to ≤50 23/31 (74.2) 10/17 (58.8) 15.4 (–11.6 to 42.6) 19/23 (82.6) 21/26 (80.8) 1.8 ( −21.5 to 24.2) 
> 50 to ≤80 71/91 (78.0) 38/46 (82.6) −4.6 ( −17.6 to 10.7) 83/99 (83.8) 88/98 (89.8) −6.0 ( −15.8 to 3.7) 
> 80 288/362 (79.6) 149/183 (81.4) −1.9 ( −8.6 to 5.5) 492/569 (86.5) 475/559 (85.0) 1.5 ( −2.6 to 5.6) 
CI, conﬁdence interval; WBC, white blood cell. 
a Systemic signs were fever > 38 °C, hypothermia < 36 °C, elevated WBC count ( > 10 0 0 0 cells/mm 3 ) or bands > 10%. 
b Severe local signs were erythema, swelling, tenderness or warmth that was designated as ‘severe’ by the investigator. 
c > 10 0 0 0 cells/mm 3 . 
d SIRS criteria were deﬁned as presence of at least two of the following symptoms at baseline: temperature < 36 °C or > 38 °C; heart rate > 90 beats/min; respiratory rate 
> 20 breaths/min, or on blood gas, a PaCO 2 , < 32 mmHg (4.3 kPa); WBC count < 40 0 0 cells/mm 
3 or > 12 0 0 0 cells/mm 3 , or > 10% band forms (immature WBCs). 
e BMI data were missing from 5 patients in COVERS and from 3 patients in CANVAS 1 and 2. 
f CIs were calculated when the sample size for a pathogen was ≥10 patients in each treatment group using the Miettinen & Nurminen method for stratiﬁed designs 
(stratiﬁed by study) [31] . 
g Ceftaroline fosamil dosage regimens were adjusted for patients with CL Cr > 30 to ≤50 mL/min. Clinical cure rates for patients with CL Cr > 20 to < 30 mL/min ( n = 8) and 
patients with missing CL Cr data ( n = 22) in COVERS are not shown. 
Table 4 
Clinical cure rate by baseline pathogen in the medically evaluable population 
Pathogen COVERS CANVAS 1 and 2 
Ceftaroline fosamil 
[ n / N (%)] 
Vancomycin + aztreonam 
[ n / N (%)] 
Between-group 
difference (95% CI) 
Ceftaroline fosamil [ n / N 
(%)] 
Vancomycin + aztreonam 
[ n / N (%)] 
Weighted a 
between-group 
difference (95% CI) 
Gram-positive bacteria 
Staphylococcus aureus b 109/119 (91.6) 61/71 (85.9) 5.7 (–3.3 to 16.5) 352/378 (93.1) 336/356 (94.4) −1.3 (–4.9 to 2.4) 
MSSA 88/94 (93.6) 49/57 (86.0) 7.7 (–1.9 to 19.7) 212/228 (93.0) 225/238 (94.5) –1.6 (–6.3 to 2.9) 
MRSA 21/25 (84.0) 12/15 (80.0) 4.0 (–19.8 to 32.2) 142/152 (93.4) 115/122 (94.3) –0.9 (–7.0 to 5.5) 
Streptococci 
Streptococcus pyogenes 14/15 (93.3) 7/7 (100.0) –6.7 (–30.5 to 30.8) 56/56 (100.0) 56/58 (96.6) 3.9 (–2.3 to 12.6) 
Streptococcus agalactiae 5/6 (83.3) 7/9 (77.8) 5.6 (–41.2 to 44.9) 21/22 (95.5) 18/18 (100.0) N/A c 
Streptococcus 
dysgalactiae 
9/9 (100.0) 0/0 (0) N/A 13/13 (100.0) 15/16 (93.8) N/A c 
Streptococcus anginosus 
group 
16/18 (88.9) 4/4 (100.0) –11.1 (–33.4 to 40.6) 12/13 (92.3) 15/16 (93.8) N/A c 
Enterococcus faecalis 4/6 (66.7) 4/5 (80.0) –13.3 (–59.6 to 41.6) 20/25 (80.0) 22/24 (91.7) –12.6 (–34.1 to 
8.0) 
Gram-negative bacteria 
Escherichia coli 11/12 (91.7) 9/10 (90.0) 1.7 (–28.5 to 34.7) 20/21 (95.2) 19/21 (90.5) N/A c 
Klebsiella oxytoca 4/4 (100.0) 1/1 (100.0) N/A 10/12 (83.3) 6/6 (100.0) N/A c 
Klebsiella pneumoniae 5/7 (71.4) 3/4 (75.0) –3.6 (–51.1 to 52.1) 17/18 (94.4) 13/14 (92.9) N/A c 
Morganella morganii 4/4 (100.0) 2/2 (100.0) N/A 11/12 (91.7) 5/6 (83.3) N/A c 
Proteus mirabilis 6/7 (85.7) 2/2 (100.0) –14.3 (–53.5 to 58.4) 10/15 (66.7) 20/21 (95.2) N/A c 
CI, conﬁdence interval; MSSA, methicillin-susceptible S. aureus ; MRSA, methicillin-resistant S. aureus ; N/A, not applicable. 
a Weighted difference in clinical cure rates stratiﬁed by study. 
b Patients with MRSA and MSSA were counted only once. 
c CIs were calculated when the sample size for a pathogen was ≥10 patients in each treatment group using the Miettinen & Nurminen method for stratiﬁed designs 
(stratiﬁed by study) [31] . 
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a  3.4. Safety 
In COVERS, 45.8% (232/506) of patients treated with ceftaroline
fosamil experienced at least one adverse event (AE) compared with
45.5% (116/255) of patients treated with vancomycin plus aztre-
onam; and 44.7% (309/692) of patients treated with ceftarolineosamil and 47.5% (326/686) of patients treated with vancomycin
lus aztreonam experienced at least one AE in the CANVAS tri-
ls. The most common AEs among ceftaroline fosamil-treated pa-
ients in COVERS (occurring in ≥3% of patients) were nausea (4.0%),
eadache (3.4%) and hypokalaemia (3.0%). The most common AEs
mong ceftaroline fosamil-treated patients in CANVAS 1 and 2
G.R. Corey, M.H. Wilcox and J. Gonzalez et al. / International Journal of Antimicrobial Agents 53 (2019) 830–837 835 
Fig. 1. Comparison of predicted steady-state ceftaroline fosamil exposures (AUC ss and C max,ss ) in individual acute bacterial skin and skin-structure infection (ABSSSI) patients 
from COVERS (A) with and without systemic inﬂammatory response syndrome (SIRS), (B) with and without fever, (C) with and without high C-reactive protein (CRP), 
(D) with and without high white blood cell count and (E) with and without bacteraemia. AUC ss , area under the concentration–time curve at steady-state; C max,ss , maximum 
plasma concentration at steady-state. 
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a(occurring in ≥3% of patients) were nausea (5.9%), headache (5.2%),
diarrhoea (4.9%), pruritus (3.5%) and rash (3.2%). 
3.5. Population pharmacokinetic modelling of ceftaroline exposure 
Overall, the population PK modelling data set included data
from 951 subjects, of which 463 were patients with cSSTI. The
model described the observed ceftaroline concentration data well
and was considered suitable to calculate exposure parameters for
individual patients in COVERS. PK data were available from 371
patients in COVERS for whom a full ceftaroline plasma concen-
tration time course could be calculated. Individual predictions of
AUC ss and C max , ss for these patients are summarised by the pres-
ence or absence of fever, SIRS or bacteraemia, high WBC count and
CRP levels in Fig. 1 . The individual, median and range AUC ss and
C max,ss values demonstrated clear evidence of overlap in patients
within the respective disease severity parameters, indicating that
these parameters had little effect on ceftaroline exposure. 
4. Discussion 
The COVERS and CANVAS 1 and 2 trials included all patients
with systemic signs of inﬂammation, or sepsis, and SIRS, allowing
for an informative comparison of the clinical outcomes associated
with ceftaroline fosamil 600 mg as a 1-h infusion q8h versus 600
mg as a 2-h infusion q12h in patients with severe ABSSSI. Because
the pathogens isolated and their associated ceftaroline susceptibili-
ties in the COVERS trial were similar to the CANVAS trials, the clin-
ical outcomes and pathogen susceptibilities were compared. This
provides further rationale for the comparison of clinical outcomes
between the trials. Moreover, a patient-rich population ceftaroline
PK model, which included data from over 900 subjects, allowed
evaluation of predicted ceftaroline exposures for patients with and
without sepsis, complementing the clinical data comparisons be-
tween the trials. 
Although the ceftaroline fosamil q8h dosage regimen was ef-
ﬁcacious in COVERS, clinical outcomes among ceftaroline fosamil-
treated patient subgroups with more severe disease (i.e. more than
one systemic sign of inﬂammation, or sepsis, fever, elevated WBC
count or SIRS) were comparable with patients receiving ceftaro-
line fosamil q12h in the CANVAS trials. Clinical cure rates were
also generally comparable for BMI and CL Cr patient subgroups in
the COVERS and CANVAS trials. Differences in clinical cure rates
for ceftaroline fosamil versus vancomycin plus aztreonam were
broadly similar across the trials; for both treatment groups, clinical
cure rates were generally numerically lower in COVERS compared
with the CANVAS trials. This is likely due to patients generally hav-
ing more severe infection and co-morbidities that are not captured
in a single subgroup category. Ceftaroline fosamil was well toler-
ated in both trials, with AEs representative of the cephalosporin
class. Hence, the q12h regimen appears robust for the majority of
patients with ABSSSI, regardless of the presence of systemic in-
ﬂammatory signs. 
These clinical data are aligned with population PK modelling
of individual patients within the COVERS trial, which showed that
steady-state exposures of ceftaroline were comparable across pa-
tients with and without signs of sepsis. The pharmacokinetics of
ceftaroline in COVERS was similar to results previously reported
for subjects treated with ceftaroline fosamil q12h [18,33] , with a
dose-proportional increase in exposure from the q8h dosing used
in COVERS [30,33,34] . Ceftaroline pharmacokinetics therefore does
not appear to be affected by disease severity, suggesting that the
ceftaroline fosamil q12h regimen provides adequate exposure in
ABSSSI patients with severe disease. Pathogen susceptibilities to
ceftaroline were similar between the COVERS and CANVAS trials,ith both dosage regimens providing broad coverage against com-
only isolated ABSSSI pathogens. The MICs of > 95% of baseline
solates across the three trials were at or below respective CLSI
nd European Committee on Antimicrobial Susceptibility Testing
EUCAST) susceptibility breakpoints for ceftaroline fosamil 600 mg
12h [16,35] . Clinical response rates were generally comparable
cross the COVERS and CANVAS trials for key ABSSSI pathogens,
ncluding S. aureus . MRSA isolated from COVERS and CANVAS 1
nd 2 had ceftaroline MICs of ≤1 mg/L and ≤2 mg/L, respectively.
robability of target attainment (PTA) analyses using the ceftaro-
ine population PK model described above have shown that > 95%
TA is predicted with the 600 mg q12h dose regimen for S. au-
eus isolates with MICs up to 2 mg/L [30] . With the 600 mg q8h
osage regimen, > 95% PTA is predicted for S. aureus isolates with
ICs up to 4 mg/L [30] . In 2017, the EMA label was updated to
ecommend the use of ceftaroline fosamil 600 mg q8h for cSSTI
atients where the causative pathogen is S. aureus with a ceftaro-
ine MIC of 2 mg/L or 4 mg/L [8] ; such isolates are very rare in the
SA and Europe [36,37] . 
Because individual study patient PK data were not analysed in
his retrospective analysis and individual patients may have differ-
nt disease states, this was not described in the CANVAS and COV-
RS trials. We believe that confounders that do exist in this partic-
lar patient population are valid but, given the positive ﬁndings in
his study, do not appear to play a substantial role in the eﬃcacy
r toxicity of ceftaroline treatment. In addition, because this anal-
sis is a retrospective cross-trial comparison, it is limited by the
nability to completely control for population differences between
rials. Similarly, as enrolment for COVERS and the CANVAS trials
ccurred in different geographic locations, regional differences in
are may have affected the results. However, given that the pop-
lation PK analyses support the conclusions from the cross-trial
omparison, the data overall support that ceftaroline fosamil 600
g q12h is a robust dosage regimen for the great majority of pa-
ients with ABSSSI, including those with sepsis and SIRS. 
. Conclusions 
On the basis of the clinical, microbiological and population PK
odelling comparisons presented here, sepsis did not affect pre-
icted individual steady-state ceftaroline exposure. Ceftaroline fos-
mil 600 mg q12h is a well-tolerated, eﬃcacious dosage regimen
or the majority of patients with severe ABSSSI, regardless of the
xtent of sepsis. 
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